In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium – A proof of concept study

Kawabata, 2011, Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications, Int. J. Pharm., 420, 1, 10.1016/j.ijpharm.2011.08.032 Fahr, 2007, Drug delivery strategies for poorly water-soluble drugs, Expert Opin. Drug Deliv., 4, 403, 10.1517/17425247.4.4.403 Dengale, 2016, Recent advances in co-amorphous drug formulations, Adv. Drug Deliv. Rev., 100, 116, 10.1016/j.addr.2015.12.009 Serajuddin, 1999, Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs, J. Pharm. Sci., 88, 1058, 10.1021/js980403l Priemel, 2013, In situ amorphisation of indomethacin with Eudragit® E during dissolution, Eur. J. Pharm. Biopharm., 85, 1259, 10.1016/j.ejpb.2013.09.010 Doreth, 2016, Glass solution formation in water - In situ amorphization of naproxen and ibuprofen with Eudragit® E PO, J. Drug Del. Sci. Tech., 34, 32, 10.1016/j.jddst.2016.02.003 Doreth, 2017, Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin, Eur. J. Pharm. Biopharm., 122, 62, 10.1016/j.ejpb.2017.10.001 Lim, 2016, Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling, J. Pharm. Pharmacol., 68, 36, 10.1111/jphp.12494 Löbmann, 2011, Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen, Mol. Pharm., 8, 1919, 10.1021/mp2002973 Shayanfar, 2013, Drug–drug coamorphous systems: characterization and physicochemical properties of coamorphous atorvastatin with carvedilol and glibenclamide, J. Pharm. Innov., 8, 218, 10.1007/s12247-013-9162-1 Löbmann, 2013, Amino acids as co-amorphous stabilizers for poorly water soluble drugs-Part 1: preparation, stability and dissolution enhancement, Eur. J. Pharm. Biopharm., 85, 873, 10.1016/j.ejpb.2013.03.014 Laitinen, 2014, Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability, Mol. Pharm., 11, 2381, 10.1021/mp500107s Jensen, 2015, Formation mechanism of coamorphous drug-amino acid mixtures, Mol. Pharm., 12, 2484, 10.1021/acs.molpharmaceut.5b00295 Kasten, 2016, Development of a screening method for co-amorphous formulations of drugs and amino acids, Eur. J. Pharm. Sci., 95, 28, 10.1016/j.ejps.2016.08.022 Ali, 2015, Clozapine-carboxylic acid plasticized co-amorphous dispersions: preparation, characterization and solution stability evaluation, Acta Pharmaceutica, 65, 133, 10.1515/acph-2015-0014 Chavan, 2016, Co amorphous systems: a product development perspective, Int. J. Pharm., 515, 403, 10.1016/j.ijpharm.2016.10.043 Lenz, 2015, Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine, Eur. J. Pharm. Biopharm., 96, 44, 10.1016/j.ejpb.2015.07.011 Petry, 2017, Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect, Eur. J. Pharm. Biopharm., 119, 150, 10.1016/j.ejpb.2017.06.007 Jensen, 2016, Influence of variation in molar ratio on co-amorphous drug-amino acid systems, Eur. J. Pharm. Biopharm., 107, 32, 10.1016/j.ejpb.2016.06.020 Pitt, 1988, Tensile fracture of doubly-convex cylindrical discs under diametral loading, J. Mater. Sci., 23, 2723, 10.1007/BF00547442 Cipiciani, 1983, Kinetics and mechanism of the basic hydrolysis of indomethacin and related compounds: A reevaluation, J. Pharm. Sci., 72, 1075, 10.1002/jps.2600720928 Youm, 2013, Validated reverse-phase high-performance liquid chromatography for quantification of furosemide in tablets and nanoparticles, J. Anal. Methods Chem., 2013, 1, 10.1155/2013/207028 Danley, 2003, New heat flux DSC measurement technique, Thermochim. Acta, 395, 201, 10.1016/S0040-6031(02)00212-5 http://www.drugs.com/dosage/indomethacin, Indomethacin dosage (2018). http://www.drugs.com/dosage/furosemide, Furosemide dosage (2018). Petry, 2018, Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions, Int. J. Pharm., 544, 172, 10.1016/j.ijpharm.2018.04.026 EUDRAGIT® Application Guidelines, 12 ed., Evonik Industries, Darmstadt, Germany. Rowe, 2010 Agyilirah, 1991 Tanabe, 2012, Yellow coloration phenomena of incorporated indomethacin into folded sheet mesoporous materials, Int. J. Pharm., 429, 38, 10.1016/j.ijpharm.2012.03.011 Hulse, 2009, The characterization and comparison of spray-dried mannitol samples, Drug Dev. Ind. Pharm., 35, 712, 10.1080/03639040802516491 Burger, 2000, Energy/Temperature diagram and compression behavior of the polymorphs of d-mannitol, J. Pharm. Sci., 89, 457, 10.1002/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO;2-G Wu, 2017, On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems, Int. J. Pharm., 535, 86, 10.1016/j.ijpharm.2017.10.057 Jensen, 2016, Preparation and characterization of spray-dried co-amorphous drug-amino acid salts, J. Pharm. Pharmacol., 68, 615, 10.1111/jphp.12458 Lenz, 2017, Hot melt extrusion and spray drying of co-amorphous indomethacin-arginine with polymers, J. Pharm. Sci., 106, 302, 10.1016/j.xphs.2016.09.027 Löbmann, 2013, Amino acids as co-amorphous stabilizers for poorly water-soluble drugs-Part 2: molecular interactions, Eur. J. Pharm. Biopharm., 85, 882, 10.1016/j.ejpb.2013.03.026